urocore.com
May 30, 2025, 09:55
ASCO25 Update: Tres Uramigas Highlighted Data on ADC and PD-1 Combinations in Bladder Cancer
Tres Uramigas shared a post on X:
“ASCO25: ADC/PD-1 combos data in Bladder Cancer.
Nectin4/PD-1 response rates similar to EVP
DV/Toripalimab exceeds QT in 1L. A new therapeutic scenario opens up in which QT could cease to be SoC in 1L.”
More posts featuring ASCO 2025.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 9, 2025, 11:56
Jul 9, 2025, 10:27
Jul 9, 2025, 10:27
Jul 9, 2025, 09:56